QQ客服 官方微博 反馈留言

浏览/检索结果: 共4条，第1-4条 帮助 限定条件 发表日期：2020     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer 期刊论文 JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2020, 卷号: 39 作者:  Ma, Liying;  Bian, Xing;  Lin, Wenchu 收藏  |  浏览/下载：38/0  |  提交时间：2020/11/30 SCLC  PI3K  HDAC  CUDC-907  PARP1  Olaparib  DSB repair  Combination treatment   Emerging roles of class I PI3K inhibitors in modulating tumor microenvironment and immunity 期刊论文 ACTA PHARMACOLOGICA SINICA, 2020, 页码: 8 作者:  Sun, Pu;  Meng, Ling-hua 收藏  |  浏览/下载：39/0  |  提交时间：2020/12/21 phosphoinositide 3-kinase (PI3K)  PI3K inhibitors  tumor microenvironment  immune cells  immunotherapy   PI3K/Akt pathway is involved in the activation of RAW 264.7 cells induced by hydroxypropyltrimethyl ammonium chloride chitosan 期刊论文 JOURNAL OF OCEANOLOGY AND LIMNOLOGY, 2020, 卷号: 38, 期号: 3, 页码: 834-840 作者:  Yang Yue;  Xing Rong'e;  Liu Song;  Qin Yukun;  Li Kecheng 收藏  |  浏览/下载：30/0  |  提交时间：2020/09/24 hydroxypropyltrimethyl ammonium chloride chitosan  RAW 264  7 cells  PI3K  Akt pathway  nuclear factor-kappa B  activating protein 1   Upfront dose-reduced chemotherapy synergizes with immunotherapy to optimize chemoimmunotherapy in squamous cell lung carcinoma 期刊论文 JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 卷号: 8, 期号: 2, 页码: 15 作者:  He, Xiran;  Du, Yang;  Wang, Zhijie;  Wang, Xin;  Duan, Jianchun 收藏  |  浏览/下载：28/0  |  提交时间：2021/01/06 drug therapy  combination  immunotherapy  lung neoplasms  lymphocytes  tumor-infiltrating  translational medical research